| Literature DB >> 29057053 |
Jiney Jose1,2, Clint D J Tavares1,3, Nancy D Ebelt1,3, Alessia Lodi4, Ramakrishna Edupuganti1,2, Xuemei Xie5,6, Ashwini K Devkota1,3, Tamer S Kaoud1, Carla L Van Den Berg3,7, Eric V Anslyn2, Stefano Tiziani4, Chandra Bartholomeusz5,6, Kevin N Dalby1,3.
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is a critical local regulator of epithelial homeostasis in the breast and exerts its actions through a number of receptors. Dysregulation of serotonin signaling is reported to contribute to breast cancer pathophysiology by enhancing cell proliferation and promoting resistance to apoptosis. Preliminary analyses indicated that the potent 5-HT1B/1D serotonin receptor agonist 5-nonyloxytryptamine (5-NT), a triptan-like molecule, induced cell death in breast cancer cell lines. Thus, we synthesized a series of novel alkyloxytryptamine analogues, several of which decreased the viability of various human cancer cell lines. Proteomic and metabolomic analyses showed that compounds 6 and 10 induced apoptosis and interfered with signaling pathways that regulate protein translation and survival, such as the Akt/mTOR pathway, in triple-negative breast cancer cells.Entities:
Keywords: Breast cancer; serotonin receptor; tryptamine
Year: 2017 PMID: 29057053 PMCID: PMC5641961 DOI: 10.1021/acsmedchemlett.7b00282
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345